Updated:
BioForce Nanosciences Holdings
Kerry Frey controls BioForce Nanosciences Holdings, a custodianship-acquired public shell with no disclosed investments or operations.
BioForce Nanosciences Holdings
BioForce Nanosciences Holdings, Inc. took its current form when CEO Kerry Frey assumed control through a custodianship in Nevada in 2022, acquiring the defunct Virginia Beach-based biotech's public shell. The original company, founded in the 1990s, developed the Nano eNabler molecular printer before ceasing operations. The entity now exists as an SEC-filing OTC ticker with minimal assets and no known operating business. The company has disclosed no investment strategy, asset-class allocation, or deployment activity since Frey's custodianship. Public filings confirm the entity holds no meaningful revenue, no portfolio companies, and no disclosed investment positions. No fund vehicles, SPVs, or co-investment structures have been reported to shareholders or regulators. The company reports a single officer — CEO Kerry Frey — with no additional investment professionals, advisory board, or disclosed office locations beyond the legacy Virginia Beach address. No family office structural details, wealth origin information, or adjacent vehicles have been publicly documented. In May 2024, the company filed its quarterly OTC Markets disclosure, confirming continued reporting status but zero operational activity. The entity's structural differentiator is its condition as a custodianship-acquired public shell — a regulatory artifact, not an operating family office — with no demonstrated mandate, capital base, or investment program. Its only tangible attribute is its SEC reporting obligation, which sustains a public listing without fulfilling the economic function of a family office or investment vehicle.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Virginia Beach
Corporate office
Virginia Beach, VA, United States
Principals
Kerry Frey
CEO
Frequently asked questions
Who controls BioForce Nanosciences Holdings and how did they acquire it?
Kerry Frey gained control of the entity in 2022 through a Nevada custodianship proceeding, a legal mechanism used to revive defunct public companies. The original firm, a biotech instrument maker founded in the 1990s, had ceased operations and abandoned its SEC reporting obligations. Frey serves as the sole officer and director.
Does BioForce Nanosciences Holdings make investments or operate a family office?
No. Since the custodianship acquisition, the company has filed disclosures confirming zero operational revenue and no material assets. It has not announced any investment strategy, portfolio holdings, or family office structure. It remains a public shell reporting entity.
What happened to the original BioForce Nanosciences business?
The original company developed the Nano eNabler, a molecular-scale printing instrument for biological applications, in the early 2000s. The business failed to achieve commercial viability and ceased operations years before the public shell was acquired through custodianship.
Is this entity a single family office or multi-family office?
Neither. Despite the entity's classification as a holding company, it does not function as a family office in practice. No family wealth has been attributed to it, no investment team exists, and no client or family capital is reported. The corporate form does not match any conventional family office model.
Does BioForce Nanosciences Holdings file with the SEC?
Yes. The company maintains its SEC reporting status and files periodic disclosures as a public entity. These filings consistently indicate no revenue, operations, or material assets — keeping the shell alive without fulfilling any investment mandate.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: